Obexelimab
Monoclonal antibody
Evidence outlook · regulatory review
IgG4-Related Disease: application under FDA review
FDA accepts obexelimab BLA for IgG4-related disease (2026-08). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.
Also in development:Systemic Lupus Erythematosus · Phase 2
Company guidance: regulatory filing expected second half of 2026 (Zenas BioPharma, 13 Aug 2026). “We intend to submit a supplemental application to obexelimab’s IgG4-RD BLA, if approved, and to include the bioequivalence data to a European MAA submission in the second half of 2026.” Source ↗
Company guidance: topline data expected Q4 2026 (NCT06559163; Zenas BioPharma, 13 Aug 2026). “Obexelimab global Phase 2 SunStone SLE trial topline results expected in Q4 2026 -” Source ↗
Company guidance: topline data expected by year-end (Zenas BioPharma, 13 Aug 2026). “Beyond IgG4-RD, we are on track to report Phase 2 topline data for obexelimab in SLE and initial Phase 1 data for ZB021 by year-end.” Source ↗
The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Systemic Lupus Erythematosus: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Obexelimab: this drug | Phase 2 | Monoclonal antibody | CD19 / FcγRIIb | Partial signal | NCT02725515: Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 225 (Day 225): XmAb5871 21/50 vs Placebo 12/42 missed | |
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor subunit 1 (IFNAR1) | Partial signal | NCT04931563: Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo (Week 52): Anifrolumab 300mg 84/138 vs Placebo 46/138 NCT02446899: Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 (Baseline; Week 52): Anifrolumab 300 mg 86/180 (47.8%) vs Placebo 57/182 (31.3%) | |
| Belimumab (GSK1550188) (Benlysta) | Approved | Monoclonal antibody | BAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS) | Weak signal | NCT00410384: SRI response at Week 52: 43.2% with belimumab 10 mg/kg vs 33.5% with placebo (p=0.0167); 40.6% with belimumab 1 mg/kg vs 33.5% with placebo (p=0.0889). | |
| Hydroxychloroquine | Approved | Small molecule | Autophagy/lysosomal acidification | not yet graded | No reviewed efficacy summary in this indication | |
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Deucravacitinib (Sotyktu) | Phase 3 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Litifilimab | Phase 3 | Monoclonal antibody | BDCA2 (CLEC4C), BDCA2 / CD303 (blood dendritic cell antigen 2) | Reliable signal | NCT02847598: Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 (Baseline to Week 24): Part A: BIIB059 50 mg -9 joints (Standard Deviation 5.7) | Part A: BIIB059 150 mg -13 joints | Part A: BIIB059 450 mg -14.5 joints (Standard Deviation 8.7) vs Part A: Placebo -12.7 joints (Standard Deviation 10.3) | |
| Obinutuzumab Beta (Bejescin) | Phase 3 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Upadacitinib (Rinvoq) | Phase 3 | Small molecule | JAK, JAK1 | not yet graded | No reviewed efficacy summary in this indication | |
| Voclosporin (Lupkynis) | Phase 3 | Small molecule | Calcineurin, Cyclophilin A (leading to calcineurin inhibition) | Reliable signal | No reviewed efficacy summary in this indication | |
| Afimetoran | Phase 2 | Small molecule | TLR7/8 | not yet graded | No reviewed efficacy summary in this indication | |
| BI 3000202 | Phase 2 | Small molecule | cGAS (cyclic GMP-AMP synthase) | not yet graded | No reviewed efficacy summary in this indication | |
| Blinatumomab | Phase 2 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Envudeucitinib | Phase 2 | Small molecule | TYK2 | Partial signal | NCT05966480: LUMUS trial (NCT05966480), primary endpoint BICLA response: envudeucitinib did not meet its primary endpoint in the overall trial population, but a prespecified IFNGS-high subgroup showed robust clinical responses on the same primary endpoint (BICLA). missed | |
| Frexalimab | Phase 2 | Monoclonal antibody | CD40 ligand (CD40L / CD154) | not yet graded | No reviewed efficacy summary in this indication | |
| FT819 | Phase 2 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| ICG318 | Phase 2 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Inebilizumab | Phase 2 | Monoclonal antibody | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Nomelcitinib (D-2570) | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sanritatug | Phase 2 | Monoclonal antibody | CD38 | Weak signal | No reviewed efficacy summary in this indication | |
| TQH3906 | Phase 2 | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication | |
| VENT-03 | Phase 2 | Small molecule | cGAS (cyclic GMP-AMP synthase) | not yet graded | No reviewed efficacy summary in this indication | |
| Zolacabtagene Autoleucel | Phase 2 | Cell therapy | — | not yet graded | No reviewed efficacy summary in this indication | |
| Aritinercept | Phase 1/2(overall) | Protein / enzyme therapeutic | BAFF / APRIL | not yet graded | No reviewed efficacy summary in this indication | |
| AZD0120 | Phase 1/2 | Cell therapy | BCMA / CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Beijing Biotech Anti-CD19 CAR-T | Phase 1/2 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Budoprutug | Phase 1/2 | Monoclonal antibody | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| DS-7011a | Phase 1/2 | Monoclonal antibody | Toll-like receptor 7 (TLR7) (inhibitor) | Weak signal | NCT05638802: Treatment-emergent adverse events: 11/19 DS-7011a participants vs 4/6 placebo participants. | |
| Lisaftoclax | Phase 1/2 | Small molecule | BCL-2 | not yet graded | No reviewed efficacy summary in this indication | |
| SCTC21C | Phase 1/2 | Biologic (subtype unspecified) | CD38 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-319 | Phase 1 | Antibody–drug conjugate | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-519 | Phase 1 | — | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| ANX009 | Phase 1 | Antibody fragment | C1q | not yet graded | No reviewed efficacy summary in this indication | |
| AZD5492 | Phase 1 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| BCD-256 | Phase 1 | Monoclonal antibody | BDCA2 (CLEC4C) | not yet graded | No reviewed efficacy summary in this indication | |
| BCMA-CD19 Compound CAR (cCAR) T Cells | Phase 1 | Cell therapy | BCMA / CD19 | Weak signal | NCT05474885: All patients (12/13) who received an initial dose of 3x10^6 cCAR cells/kg were negative for all autoantibodies, including those derived from long-lived plasma cells, 3 months post-cCAR. Therapy was well tolerated with mild cytokine-release syndrome (no CRS above grade 1), and mean SLE Disease Activity Index 2000 (SLEDAI-2K) fell from 9.9 at baseline to 2.3 at 3 months. | |
| BZE2204 | Phase 1 | Cell therapy | CD19, CD22, and BCMA (tri-antigen) | not yet graded | No reviewed efficacy summary in this indication | |
| Cevostamab | Phase 1 | Multispecific antibody | FcRH5 (FcRL5) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Cizutamig | Phase 1 | Multispecific antibody | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| CLN-978 | Phase 1 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Divozilimab (Ivlizi) | Phase 1 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| F01 | Phase 1 | Cell therapy | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK4527363 | Phase 1 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK5926371 | Phase 1 | Biologic (subtype unspecified) | CD19 / CD20 (dual-antigen) with CD3 T-cell engagement | not yet graded | No reviewed efficacy summary in this indication | |
| HC022 | Phase 1 | — | — | Weak signal | No reviewed efficacy summary in this indication | |
| IC19 CAR-T | Phase 1 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| LBL-047 | Phase 1 | Protein / enzyme therapeutic | BDCA2 (CLEC4C) / TACI | not yet graded | No reviewed efficacy summary in this indication | |
| NIM-1324 | Phase 1(overall) | Small molecule | LANCL2 | not yet graded | No reviewed efficacy summary in this indication | |
| Odronextamab | Phase 1 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| PIT565 | Phase 1 | Multispecific antibody | CD19 x CD2 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| SAR448501 | Phase 1 | Multispecific antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Surovatamig | Phase 1 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| UTAA09 | Phase 1 | Cell therapy | CD19 | Weak signal | No reviewed efficacy summary in this indication | |
| UTAA91 | Phase 1 | Cell therapy | CD19 (B cells) and PD-1+ pathogenic T cells | not yet graded | No reviewed efficacy summary in this indication | |
| Vonsetamig | Phase 1 | — | BCMA x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| ZM001 | Phase 1 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| Zugocabtagene Geleucel | Phase 1 | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| FT522 | —(overall) | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication | |
| GRI-0803 | —(overall) | Small molecule | Type 2 NKT cells (activator) | not yet graded | No reviewed efficacy summary in this indication | |
| AB-101 (AlloNK) | Discontinued | Cell therapy | Cell therapy | not yet graded | No reviewed efficacy summary in this indication | |
| Cadefrecitinib | Discontinued | Small molecule | TYK2 | not yet graded | No reviewed efficacy summary in this indication |
Large race: only the 60 furthest-along competitors are listed; 3 more exist in this indication but aren't shown. Use the search box to compare against any of them.
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Coming up
Recent